BTK Inhibition in CSU: What PA/NPs Need to Know

Once CSU remains uncontrolled despite antihistamines, newer mechanisms have widened the choices clinicians can bring into the conversation. David Seiter, FNP-C, takes a closer look at BTK inhibition with remibrutinib, explaining how an intracellular target differs from other advanced approaches and why that may matter across CSU endotypes. He also walks through the practical considerations PA/NPs need at the point of care, including expected response, petechiae and other safety counseling, and how to prepare patients for what they may notice after treatment begins.